Gottifredi Vanesa, Wiesmüller Lisa
Fundación Instituto Leloir, IIBBA-Consejo Nacional de Investigaciones Científicas y Técnicas. Av. Patricias Argentinas 435, 1405 Buenos Aires, Argentina.
Division of Gynecological Oncology, Department of Obstetrics and Gynecology of the University of Ulm Prittwitzstrasse 43, 89075 Ulm, Germany.
Cancers (Basel). 2020 Mar 17;12(3):705. doi: 10.3390/cancers12030705.
In this Special Issue, we would like to focus on the various functions of the RAD52 helicase-like protein and the current implications of such findings for cancer treatment. Over the last few years, various laboratories have discovered particular activities of mammalian RAD52-both in S and M phase-that are distinct from the auxiliary role of yeast RAD52 in homologous recombination. At DNA double-strand breaks, RAD52 was demonstrated to spur alternative pathways to compensate for the loss of homologous recombination functions. At collapsed replication forks, RAD52 activates break-induced replication. In the M phase, RAD52 promotes the finalization of DNA replication. Its compensatory role in the resolution of DNA double-strand breaks has put RAD52 in the focus of synthetic lethal strategies, which is particularly relevant for cancer treatment.
在本期特刊中,我们将聚焦于RAD52解旋酶样蛋白的多种功能以及这些发现目前对癌症治疗的影响。在过去几年中,各个实验室已经发现了哺乳动物RAD52在S期和M期的特定活性,这些活性不同于酵母RAD52在同源重组中的辅助作用。在DNA双链断裂处,RAD52被证明能促进替代途径以弥补同源重组功能的丧失。在复制叉坍塌时,RAD52激活断裂诱导复制。在M期,RAD52促进DNA复制的完成。它在DNA双链断裂修复中的补偿作用使RAD52成为合成致死策略的焦点,这对癌症治疗尤为重要。